EXPERT INSIGHTS
A media library featuring your peers discussing clinical data and their clinical experience in prescribing RINVOQ.1
GUT REACTIONS PODCAST
Gut Reactions brings in-depth conversations, professional insights, and experience to your podcast rotation. Tune in, as leading gastroenterologists gather for one-on-one conversations with host David Rubin, MD.
DR. RUBIN
Dr. Rubin is a professor and practitioner of medicine, Chief, Section of Gastroenterology, Hepatology and Nutrition and the Co-Director of the Digestive Diseases Center at The University of Chicago Medicine. He is a renowned gastroenterologist specializing in the assessment and treatment of digestive diseases including IBD (Crohn’s disease and ulcerative colitis). Gut Reactions will feature his discussions around the evolving treatment landscape and patient outcomes.
Description
Dr. Rubin welcomes guest Dr. Oriana Damas, IBD Physician Scientist and Director of Translational Studies at the University of Miami Crohn’s and Colitis Center, to discuss the importance of objective measures in UC, such as endoscopic improvement and histo-endoscopic mucosal improvement, and their place in your clinical practice.
Click here for Prescribing Information, including BOXED WARNING, of the treatment option mentioned within this podcast.
EPISODE 1: OBJECTIVE MEASURES AND ENDOSCOPIC IMPROVEMENT
In this episode, Oriana M. Damas, MD, MSCTI joins Dr. Rubin for a discussion on the importance of objective measures in UC—such as endoscopic improvement and histo-endoscopic mucosal improvement—and how they fit into your clinical practice.
The discussion will also include an exploration of the RINVOQ (upadacitinib) data demonstrating endoscopic improvement of the colon.
Description
Dr. Rubin and guest Dr. Josh Steinberg, a board-certified gastroenterologist and director of IBD at Gastroenterology of the Rockies, discuss treatment goals and setting expectations for UC patients, evaluating loss of response, and interpreting objective measures of patients who may need a treatment change. The two also share their personal experiences with transitioning patients to an appropriate therapy.
Click here for Prescribing Information, including BOXED WARNING, of the treatment option mentioned within this podcast.
EPISODE 2: THE SWITCH-READY PATIENT
A loss of response does not mean a loss of getting UC under control. Dr. Rubin brings Josh Steinberg, MD to the table to discuss the evaluation of primary and secondary loss of response, and identifying moderate to severe UC patients that are inadequately responding to a TNFi who may need a treatment change.
From there, they share their personal experience with switching those patients to RINVOQ (upadacitinib).
